Q1 2025 EPS Estimates for Edwards Lifesciences Co. (NYSE:EW) Cut by Leerink Partnrs

Edwards Lifesciences Co. (NYSE:EW) – Leerink Partnrs lowered their Q1 2025 EPS estimates for shares of Edwards Lifesciences in a research note issued on Wednesday, April 17th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will post earnings of $0.74 per share for the quarter, down from their prior estimate of $0.75. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.76 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ Q2 2025 earnings at $0.78 EPS, Q3 2025 earnings at $0.79 EPS and Q4 2025 earnings at $0.80 EPS.

Several other equities research analysts have also commented on EW. Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective for the company in a research note on Friday, February 2nd. Citigroup upped their target price on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Mizuho upped their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. One analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Trading Down 0.6 %

NYSE:EW opened at $85.94 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The firm has a market capitalization of $51.73 billion, a price-to-earnings ratio of 37.37, a price-to-earnings-growth ratio of 4.32 and a beta of 1.05. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The business has a fifty day moving average price of $90.15 and a 200-day moving average price of $78.31.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 EPS.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. In the last quarter, insiders sold 194,004 shares of company stock valued at $17,166,254. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently modified their holdings of the stock. Castleview Partners LLC purchased a new position in shares of Edwards Lifesciences during the first quarter worth approximately $25,000. DSM Capital Partners LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $28,000. Compass Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $31,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $34,000. Finally, Riverview Trust Co purchased a new position in shares of Edwards Lifesciences during the first quarter worth approximately $34,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.